teamwork

New startup accelerator emerges in Houston to promote collaboration between Black and Hispanic communities

BH Ventures is seeking Black and Hispanic entrepreneurs for its inaugural cohort. Photo via Getty Images

Two local business leaders have teamed up to create a Houston-based accelerator focused on Black and Hispanic entrepreneurs.

BH Ventures has applications open for its inaugural cohort until August 21, and co-founders Sharita M. Humphrey and Enrique Castro are looking for founders who have hit the revenue-generating phase with their business but are looking for mentors and support as they grow.

"Enrique and I know that there can sometimes be a barrier between Black and Hispanics doing business together," says Humphrey. "This is why I wanted, as an African American woman, and him, being a Hispanic male, to be able to show that we should be doing business together — especially in the city of Houston."

Humphrey and Castro met at an alumni event for the University of Houston's SURE program, which creates educational programming for entrepreneurs from under-resourced communities. The duo thought that they could create a program that built upon UH's. In February, after building out the curriculum, BH Ventures ran a successful pilot program in collaboration with UH.

Enrique Castro and Sharita M. Humphrey met at an alumni event at UH and decided to work together on an inclusive accelerator program. Courtesy photos

The seven-month program will launch virtually at the beginning of September and will work with 15 entrepreneurs across the country. Additionally, The Cannon is a partner and a resource for the program.

As of now, the program has over 20 mentors and speakers lined up, and sessions will occur virtually every other Saturday and will be a mix of presentations and Q&As with an emphasis on fostering networking connections.

"Sometimes for a Black or Hispanic entrepreneur, just being able to have that conversation or be able to ask (a mentor) certain questions and get feedback about their particular business — it's better than money," Humphrey says. "The right relationships can open up doors that money can't."

After the programming, Humphrey says BH Ventures will continue to follow each company from the cohort for 90 days in a sort of incubation period to make sure they have support after the accelerator.

"It's a lot to get the information — but how do you execute it? We're going to still follow their path," Humphrey says.

While Houston has been renown for being the most diverse city in the country, Humphrey says she's seen a shift in leadership diversity across the greater Houston area. This has motivated her to do everything she can to promote inclusion and business growth across demographics.

"(Blacks and Hispanics are) not doing as much business together as we could," Humphrey says. "And that makes no sense when we are normally at the bottom of things when it comes to finances — personal, savings, credit, wealth, business. I think that this is something that's going to be amazing for the city."

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted